MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/mds.28932

Медицинская библиотека · Movement disorders : official journal of the Movement Disorder Society · 2022

GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.

Szwedo Aleksandra A, Dalen Ingvild, Pedersen Kenn Freddy, Camacho Marta, Bäckström David, Forsgren Lars, Tzoulis Charalampos, Winder-Rhodes Sophie, Hudson Gavin, Liu Ganqiang, Scherzer Clemens R, Lawson Rachael A, Yarnall Alison J, Williams-Gray Caroline H, Macleod Angus D, Counsell Carl E, Tysnes Ole-Bjørn, Alves Guido, Maple-Grødem Jodi, Parkinson's Incidence Cohorts Collaboration

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Common genetic variance in apolipoprotein E (APOE), β-glucocerebrosidase (GBA), microtubule-associated protein tau (MAPT), and α-synuclein (SNCA) has been linked to cognitive decline in Parkinson's disease (PD), although studies have yielded mixed results.

OBJECTIVES

To evaluate the effect of genetic variants in APOE, GBA, MAPT, and SNCA on cognitive decline and risk of dementia in a pooled analysis of six longitudinal, non-selective, population-based cohorts of newly diagnosed PD patients.

METHODS

1002 PD patients, followed for up to 10 years (median 7.2 years), were genotyped for at least one of APOE-ε4, GBA mutations, MAPT H1/H2, or SNCA rs356219. We evaluated the effect of genotype on the rate of cognitive decline (Mini-Mental State Examanation, MMSE) using linear mixed models and the development of dementia (diagnosed using standardized criteria) using Cox regression; multiple comparisons were accounted for using Benjamini-Hochberg corrections.

RESULTS

Carriers of APOE-ε4 (n = 281, 29.7%) and GBA mutations (n = 100, 10.3%) had faster cognitive decline and were at higher risk of progression to dementia (APOE-ε4, HR 3.57, P < 0.001; GBA mutations, HR 1.76, P = 0.001) than non-carriers. The risk of cognitive decline and dementia (HR 5.19, P < 0.001) was further increased in carriers of both risk genotypes (n = 23). No significant effects were observed for MAPT or SNCA rs356219.

CONCLUSIONS

GBA and APOE genotyping could improve the prediction of cognitive decline in PD, which is important to inform the clinical trial selection and potentially to enable personalized treatment © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Для цитирования: Szwedo Aleksandra A, Dalen Ingvild, Pedersen Kenn Freddy, Camacho Marta, Bäckström David, Forsgren Lars, Tzoulis Charalampos, Winder-Rhodes Sophie, Hudson Gavin, Liu Ganqiang, Scherzer Clemens R, Lawson Rachael A, Yarnall Alison J, Williams-Gray Caroline H, Macleod Angus D, Counsell Carl E, Tysnes Ole-Bjørn, Alves Guido, Maple-Grødem Jodi, Parkinson's Incidence Cohorts Collaboration. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.. Movement disorders : official journal of the Movement Disorder Society. 2022. DOI: 10.1002/mds.28932.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.